Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
Eleonora Russo, Giuseppe Penno, Stefano Del Prato Department of Clinical and Experimental Medicine, Section of Diabetes and Metabolic Disease, Azienda Ospedaliero Universitaria di Pisa, and University of Pisa, Pisa, Italy Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel classified ora...
Saved in:
Main Authors: | Russo E, Penno G, Del Prato S |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2013
|
Subjects: | |
Online Access: | https://doaj.org/article/48d2c4b76bb942349b9033e8f089a3d7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
by: Gallwitz B
Published: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Bo Ahrén
Published: (2010) -
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
by: Kishimoto M
Published: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
by: Ahren B
Published: (2010) -
Alogliptin: a new addition to the class of DPP-4 inhibitors
by: Radha Andukuri, et al.
Published: (2009)